{"id":8804,"date":"2026-10-16T10:43:25","date_gmt":"2026-10-16T01:43:25","guid":{"rendered":"https:\/\/lynksolutec.com\/?post_type=news&#038;p=8804"},"modified":"2026-10-16T10:44:59","modified_gmt":"2026-10-16T01:44:59","slug":"lynk-solutec-exhibits-at-asoprs-2026-advancing-next-steps-for-u-s-market-entry","status":"publish","type":"news","link":"https:\/\/lynksolutec.com\/en\/news\/lynk-solutec-exhibits-at-asoprs-2026-advancing-next-steps-for-u-s-market-entry\/","title":{"rendered":"Lynk Solutec Exhibits at ASOPRS 2026, Advancing Next Steps for U.S. Market Entry"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">SEOUL, South Korea, October 16, 2026 \u2014 Lynk Solutec, a South Korean medical device company, exhibited at the ASOPRS 2026 Fall Scientific Symposium, held October 8-9 at the Hyatt Regency New Orleans, showcasing its LYNKS Frontalis Suspension Set, a solid silicone suspension material used in ptosis (eyelid drooping) repair surgery. The device is registered with the U.S. Food and Drug Administration (FDA) and holds a GMP Certificate of Conformity in South Korea.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Frontalis suspension surgery uses a suspension material to lift the eyelid by connecting it to the frontalis muscle, and the LYNKS Frontalis Suspension Set provides oculoplastic surgeons with a solid silicone option for this procedure. The ASOPRS Fall Scientific Symposium gathered oculoplastic surgeons and medical device distributors from across the United States, giving Lynk Solutec direct access to its target clinical audience.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Building on the exhibit, Lynk Solutec plans to advance its clinical trial in South Korea and continue discussions with prospective U.S. distribution partners as it prepares for a U.S. market launch of the LYNKS Frontalis Suspension Set.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Engaging with oculoplastic surgeons and distributors at ASOPRS 2026 confirmed strong interest in a solid silicone suspension option,&#8221; said Yeontaek Lee, CEO of Lynk Solutec. &#8220;Our next step is to advance our clinical trial in Korea and finalize distribution partnerships to bring the LYNKS Frontalis Suspension Set to the U.S. market.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"featured_media":0,"template":"","news-category":[],"class_list":["post-8804","news","type-news","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/lynksolutec.com\/en\/wp-json\/wp\/v2\/news\/8804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lynksolutec.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/lynksolutec.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/lynksolutec.com\/en\/wp-json\/wp\/v2\/media?parent=8804"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/lynksolutec.com\/en\/wp-json\/wp\/v2\/news-category?post=8804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}